Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis US FDA Inspections by Year
Novartis US FDA Inspections: 4 in FY2025, down 55.6% from a year earlier.
Latest, FY2025
4
Period ended Dec 31, 2025
Change on a year earlier
-55.6%
9 in FY2024
History
2 years
Since FY2024
Sources
1
Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf
Where the FY2025 figure comes from
“| Total inspections by the US FDA | 4 | 9”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | US FDA Inspections | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | -55.6% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 9 | – | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
Cite this data
StockData. (2026). Novartis US FDA Inspections, annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/qual-fda-inspections
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.